No Calcification, page-57

What I took from reading the article;

Minimal adverse events are less overall for Cardiocel than other products

The committee noted that there were proportionally higher adverse events for Cardiocel in Australia than rest-of-world and wondered why

The committee then queried whether there were differences in how Cardiocel was used by surgeons overseas versus in Australia and wondered whether any special expertise/techniques that overseas surgeons had should be documented in training documents so that Australian surgeons could benefit

That is; the committee seem to like the product, but query whether training/documentation is sufficient

All makes sense to me. When the committee next meets I would hope Admedus have sufficient answers to their query and that Cardiocel can be approved for use.